{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T15:49:01Z","timestamp":1771861741469,"version":"3.50.1"},"reference-count":46,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"unspecified","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Open Research Fund of Hubei Key Laboratory of Precision Radiation Oncology","award":["jzfs002"],"award-info":[{"award-number":["jzfs002"]}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-HS202102-0152"],"award-info":[{"award-number":["Y-HS202102-0152"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Project of Key Research and Development of Hubei Province","award":["2022BCA021"],"award-info":[{"award-number":["2022BCA021"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172977"],"award-info":[{"award-number":["82172977"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019537","name":"Science Fund for Distinguished Young Scholars of Hubei Province","doi-asserted-by":"publisher","award":["2025AFA104"],"award-info":[{"award-number":["2025AFA104"]}],"id":[{"id":"10.13039\/501100019537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,11,13]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Chemotherapy is the standard second-line treatment option for advanced biliary tract cancer (BTC), but its therapeutic efficacy is suboptimal. Disitamab vedotin (RC48) and lenvatinib have demonstrated promising efficacy in human epidermal growth factor receptor 2 (HER2)-positive BTC and other malignancies. In this study, we aim to evaluate the efficacy and safety of RC48 in combination with lenvatinib in second-line or above treatment for HER2-positive advanced BTC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This is a single-centre, single-arm, open-label, exploratory phase II clinical study in patients with HER2-positive unresectable locally advanced or metastatic BTC who have failed prior therapy. 31 patients will be enrolled in this study to receive the combination of RC48 and lenvatinib. The primary study endpoint is objective response rate, and the secondary study endpoints are disease control rate, duration of response, progression-free survival and overall survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study has received approval from the Medical Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (approval No. (2023)0367-01). Results will be disseminated through publication in peer-reviewed journals and through other appropriate media channels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ChiCTR2300076406.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-097647","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T13:40:19Z","timestamp":1767879619000},"page":"e097647","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Disitamab vedotin in combination with lenvatinib for patients with HER2-positive unresectable locally advanced or metastatic biliary tract cancer: study protocol of a phase II clinical trial"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct02881190","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01761266","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04329429","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05540483","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05417230","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0043-6073","authenticated-orcid":false,"given":"Yongqiang","family":"Yang","sequence":"first","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Hubei Key Laboratory of Precision Radiation Oncology, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5562-3354","authenticated-orcid":false,"given":"Jinfeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Hubei Key Laboratory of Precision Radiation Oncology, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0367-8469","authenticated-orcid":false,"given":"Zilong","family":"Wu","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Hubei Key Laboratory of Precision Radiation Oncology, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9019-765X","authenticated-orcid":false,"given":"Dongen","family":"Liu","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Hubei Key Laboratory of Precision Radiation Oncology, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1013-147X","authenticated-orcid":false,"given":"Jing","family":"Tang","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Hubei Key Laboratory of Precision Radiation Oncology, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7323-0331","authenticated-orcid":false,"given":"Jun","family":"Xue","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Hubei Key Laboratory of Precision Radiation Oncology, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6558-3508","authenticated-orcid":false,"given":"Gang","family":"Wu","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Hubei Key Laboratory of Precision Radiation Oncology, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"2026010805401104000_16.1.e097647.1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0446"},{"key":"2026010805401104000_16.1.e097647.2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.21037\/hbsn.2019.01.15","article-title":"Rising trends in intrahepatic cholangiocarcinoma incidence and mortality: getting at the root cause","volume":"8","author":"Raoof","year":"2019","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2026010805401104000_16.1.e097647.3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32803"},{"key":"2026010805401104000_16.1.e097647.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0310-z"},{"key":"2026010805401104000_16.1.e097647.5","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10143108","article-title":"Chemotherapy for Biliary Tract Cancer in 2021","volume":"10","author":"Sasaki","year":"2021","journal-title":"J Clin Med"},{"key":"2026010805401104000_16.1.e097647.6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/17474124.2021.1864325","article-title":"BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care","volume":"15","author":"Rizzo","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2026010805401104000_16.1.e097647.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721"},{"key":"2026010805401104000_16.1.e097647.8","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2019.37.15_suppl.4003","article-title":"ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin \/ 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced \/ metastatic biliary tract cancers (ABC) previously-treated with cisplatin\/gemcitabine (CisGem) chemotherapy","volume":"37","author":"Lamarca","year":"2019","journal-title":"JCO"},{"key":"2026010805401104000_16.1.e097647.9","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.11798"},{"key":"2026010805401104000_16.1.e097647.10","doi-asserted-by":"crossref","first-page":"785535","DOI":"10.3389\/fonc.2022.785535","article-title":"Lenvatinib Beyond First-Line Therapy in Patients With Advanced Biliary Tract Carcinoma","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"2026010805401104000_16.1.e097647.11","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-023-01317-7","article-title":"Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study","volume":"8","author":"Shi","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026010805401104000_16.1.e097647.12","doi-asserted-by":"crossref","first-page":"1109292","DOI":"10.3389\/fimmu.2023.1109292","article-title":"Efficacy and safety of lenvatinib combined with PD-1\/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Immunol"},{"key":"2026010805401104000_16.1.e097647.13","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1053\/j.gastro.2023.01.023","article-title":"EGFR\/ERBB2 Amplifications and Alterations Associated With Resistance to Lenvatinib in Hepatocellular Carcinoma","volume":"164","author":"Lim","year":"2023","journal-title":"Gastroenterology"},{"key":"2026010805401104000_16.1.e097647.14","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-016-9645-x"},{"key":"2026010805401104000_16.1.e097647.15","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2022.2069883"},{"key":"2026010805401104000_16.1.e097647.16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02912"},{"key":"2026010805401104000_16.1.e097647.17","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/cac2.12214","article-title":"Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study","volume":"41","author":"Peng","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"2026010805401104000_16.1.e097647.18","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1200\/JCO.2021.39.15_suppl.1022","article-title":"RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies","volume":"39","author":"Wang","year":"2021","journal-title":"JCO"},{"key":"2026010805401104000_16.1.e097647.19","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076386","article-title":"Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance","volume":"383","author":"Yap","year":"2023","journal-title":"BMJ"},{"key":"2026010805401104000_16.1.e097647.20","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s10120-021-01168-7","article-title":"Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors","volume":"24","author":"Xu","year":"2021","journal-title":"Gastric Cancer"},{"key":"2026010805401104000_16.1.e097647.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30207-1"},{"key":"2026010805401104000_16.1.e097647.22","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/bjs.6788","article-title":"Disease recurrence patterns after R0 resection of hilar cholangiocarcinoma","volume":"97","author":"Kobayashi","year":"2010","journal-title":"Br J Surg"},{"key":"2026010805401104000_16.1.e097647.23","first-page":"83","article-title":"Patterns of initial disease recurrence after resection of biliary tract cancer","volume":"83","author":"Jung","year":"2012","journal-title":"Oncology (Williston Park, NY)"},{"key":"2026010805401104000_16.1.e097647.24","doi-asserted-by":"publisher","DOI":"10.5009\/gnl.2009.3.4.298"},{"key":"2026010805401104000_16.1.e097647.25","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026010805401104000_16.1.e097647.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00727-4"},{"key":"2026010805401104000_16.1.e097647.27","doi-asserted-by":"crossref","first-page":"114000","DOI":"10.1016\/j.ejca.2024.114000","article-title":"Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT)","volume":"202","author":"Roth","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026010805401104000_16.1.e097647.28","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00027-9"},{"key":"2026010805401104000_16.1.e097647.29","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.clnesp.2025.03.023","article-title":"Prognostic significance of the cachexia index (CXI) in patients with cancer: A systematic review and meta-analysis","volume":"68","author":"Bas","year":"2025","journal-title":"Clin Nutr ESPEN"},{"key":"2026010805401104000_16.1.e097647.30","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16213689","article-title":"Prognostic Value of Neutrophil-to-Eosinophil Ratio (NER) in Cancer: A Systematic Review and Meta-Analysis","volume":"16","author":"Sahin","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026010805401104000_16.1.e097647.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188391"},{"key":"2026010805401104000_16.1.e097647.32","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1200\/JCO.2021.39.3_suppl.321","article-title":"Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study","volume":"39","author":"Villanueva","year":"2021","journal-title":"JCO"},{"key":"2026010805401104000_16.1.e097647.33","first-page":"1026","article-title":"Local-regional therapy combined with toripalimab and lenvatinib in patients with advanced biliary tract cancer","volume":"13","author":"Wang","year":"2023","journal-title":"Am J Cancer Res"},{"key":"2026010805401104000_16.1.e097647.34","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/13543784.2021.1837774","article-title":"Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives","volume":"30","author":"Rizzo","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"2026010805401104000_16.1.e097647.35","doi-asserted-by":"crossref","first-page":"116522","DOI":"10.1016\/j.biopha.2024.116522","article-title":"Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions","volume":"174","author":"Yu","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"2026010805401104000_16.1.e097647.36","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1200\/JCO.2021.39.3_suppl.299","article-title":"Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study","volume":"39","author":"Meric-Bernstam","year":"2021","journal-title":"JCO"},{"key":"2026010805401104000_16.1.e097647.37","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","volume":"23","author":"Meric-Bernstam","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026010805401104000_16.1.e097647.38","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026010805401104000_16.1.e097647.39","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00336-3"},{"key":"2026010805401104000_16.1.e097647.40","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1200\/JCO.2021.39.3_suppl.320","article-title":"Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT \u2018basket\u2019 trial","volume":"39","author":"Harding","year":"2021","journal-title":"JCO"},{"key":"2026010805401104000_16.1.e097647.41","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1200\/JCO.23.00606","article-title":"Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study","volume":"41","author":"Nakamura","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026010805401104000_16.1.e097647.42","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2468-1253(22)00335-1","article-title":"Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19\u201314)","volume":"8","author":"Lee","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026010805401104000_16.1.e097647.43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.3061"},{"key":"2026010805401104000_16.1.e097647.44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CMAR.S55091","article-title":"Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab","volume":"9","author":"Sorscher","year":"2013","journal-title":"Cancer Manag Res"},{"key":"2026010805401104000_16.1.e097647.45","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1014"},{"key":"2026010805401104000_16.1.e097647.46","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1200\/JCO.2022.40.16_suppl.4006","article-title":"Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial)","volume":"40","author":"Ohba","year":"2022","journal-title":"JCO"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-097647","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T13:40:29Z","timestamp":1767879629000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-097647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,8]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bmjopen-2024-097647"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-097647","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}